TORONTO, ON / ACCESSWIRE / January 31, 2017 / Golden Share (TSXV: GSH) is pleased to provide an update on a recently completed review of compiled historical exploration work at the Shebandowan Project.

Golden Share holds 100% interest in the Shebandowan Project with various portions subject to underlying Net Smelter Royalties (NSR’s). The Project is located 65 kilometres west of Thunder Bay, Ontario, Canada. It is close to a provincial highway, railway line and high voltage power line, all crossing various parts of the Project area.

The Project is located in the Shebandowan Greenstone Belt (SGB), part of the Wawa Subprovince. The SGB displays a classic Archean greenstone belt sequence and subsequent deformation making it comparable to other notable greenstone belts that host the Hemlo, Timmins and Kirkland Lake gold camps.

The Shebandowan Gold Project contains three main zones of mineralization: JF West (Pistol Lake), Bandore Main Zone and Bandore Zone 4.

Historical* resource estimates are 155,728 ounces gold (706,000 tonnes at 6.86 g/t average, Non 43-101 Compliant) at the Bandore Main Zone and 95,668 ounces gold (616,000 tonnes at 4.84 g/t average, Non 43-101 Compliant) at the Bandore Zone 4. And there are 71,685 ounces gold (Inferred, 851,000 tonnes at 2.62 g/t average and 2.00 g/t cut off in accordance with NI 43-101) at the JF West Zone. All three deposits were drilled to approximately 500 feet (150 meters) depth. Golden Share has been focusing on identifying targets for “potential new discoveries” and re-evaluating the exploration model at the three already known deposits. Here are the Highlights drawn from the recent review of the project data base:

Thirteen (13) IP zones with medium to high ranked chargeability anomalies were identified for Phase 2 follow-up. The zones were selected primarily based on their apparent lack of or minimal diamond drill hole testing, proximity to known gold occurrences and favourable geology, structure and alteration.

Golden Share also intends to re-evaluate the historical gold deposits for lower grade bulk tonnage open pit potential where the deposits have been previously evaluated primarily on the basis of narrower somewhat higher grade zones. Based on exploration to date, open-pitable shear/stockwork—hosted gold is the most probable exploration target in the Shebandowan Project area.

Given the size of the project area, the number of recognized structural zones with associated gold occurrences and alteration and lack of extensive drill testing, Golden Share believes that the Project area has the potential to host additional yet undiscovered gold mineralization. A million or more ounces of gold from several small open-pitable gold deposits within the Project would represent a reasonable exploration model for the Shebandowan Project.

“To re-evaluate exploration model for established deposits at Shebandowan is appropriate with modern open pit mining technology improvements. Exploration efforts for new discoveries have always been the focus of Golden Share. Golden Share believes in systematic exploration to balance reward and risk, and so as to enhance shareholder value. While the Company will be advancing the Shebandowan and Berens River according to the market conditions, Golden Share will continue to look for the other attractive exploration opportunities in Ontario, Canada,” Nick Zeng, the President and CEO stated.

Details of the compilation work.

The Band Ore / Pistol Lake area was previously surveyed with IP/resistivity in a series of four surveys from 1980 to 1982. All of the surveys were done with frequency domain dipole-dipole IP, ‘a’ = 50 m, n=1-4. Three of the four surveys involved limited detail follow up with ‘a’ = 25 m or ‘a’ = 12.5 m. Line spacing varied from 60m to 200m. Total production was 177.7 km. Parts of the Band Ore / Pistol Lake areas were re-surveyed with IP in 2003, 2005 and 2008. The work was done with time domain dipole-dipole, ‘a’ =25m, n=1-6. Line spacing was 100 m to 200 m. Total production was 77.2 km.

In 2016, Golden Share’s geophysical consultant recompiled and reviewed the pre 2011 historical IP surveys completed on the property. For the 4 IP surveys from the early 1980s and the 2003 IP survey, the compilation involved: transcribing n=1 and n=2 chargeability and apparent resistivity from pseudo sections; geo-referencing ideal grids and; generating colour/line contours of n=1 apparent resistivity and chargeability.

A total of 233 IP anomalies were re-picked for the four 1980s IP surveys – 37 strong, 70 moderate and 126 weak. In addition, 31 unranked IP anomalies were available from the 2003 Quantec survey and 212 IP anomalies were available from the 2005 and 2008 surveys – 52 strong, 86 moderate and 74 weak.

In 2016, Golden Share’s geological consultant grouped the majority of IP anomalies into zones comprising generally three or more anomalies on adjacent grid lines. After grouping the IP anomalies into zones, the zones were reviewed with respect to drill hole information available within Golden Share’s digital drill hole database (lithology, alteration, mineralization and assays) and GIS based geology compilation. The review concentrated on those IP zones or subsections of IP zones with anomalies ranked medium to high. The low ranked IP anomalies may still have exploration potential. However it was decided that initial review and ground follow-up should first concentrate on higher ranked anomalies.

Thirteen (13) IP zones with medium to high ranked chargeability anomalies were identified for Phase 2 follow-up. The zones were selected primarily based on their apparent lack of or minimal diamond drill hole testing, proximity to known gold occurrences and favourable geology, structure and alteration.

Golden Share will now complete a more detailed geophysical study of the 13 selected IP zones including ranking. The ranked and refined IP zones will then be followed up on the ground with detailed mapping and prospecting of the IP zones and their immediate areas. The geological program will focus on the identification quartz-feldspar porphyry (QFP), shearing/structure and alteration all of which are intimately associated with known gold occurrences on the Property. At IP zones with ‘a’ = 50 m coverage only, some profiling with ‘a’ = 25 m IP will be considered. Additional IP might also be considered to more accurately locate the zones where positional errors in the georeferenced historic grids are recognized or uncertain. Following compilation of the ground follow-up diamond drilling may be planned where warranted.

Golden Share also intends to re-evaluate the historical gold zones on the Property (in particular Bandore Main and #4 and JF West zones) for lower grade bulk tonnage open pit potential. These occurrences appear to have been previously evaluated primarily on the basis of narrower somewhat higher grade zones. Potential lower grade zones might still be relatively small, and not of interest individually, however several small open pit zones might be of interest.

Work will include generation and interpretation of a set of sections including available historic and current Golden Share drill hole data for the Bandore Main and #4 and JF West occurrences. Where available, historic drill holes with un-sampled sections may be sampled to determine if low grade gold mineralization is present which may support a low grade bulk tonnage exploration model. While resampling, Golden Share will investigate whether screen metallic assays are warranted given the historical references to nugget gold at the Property. If supported by the drill hole compilation and possible resampling, several short confirmation holes may be considered at the core of each occurrence.

Note*: The Bandore mineral resource estimates are considered to be ‘historical’ in nature. Golden Share has not done sufficient work to classify the historical estimates as current mineral resources or mineral reserves in accordance with NI 43-101. Golden Share is not treating the historical estimates as a current mineral resource s or mineral reserves; they are presented for informational purposes only and should not be relied upon.

The technical information in this press release has been prepared in accordance with Canadian regulatory requirements set out in National Instrument 43-101 and reviewed by Wes Roberts M.Sc., P.Eng‎., a Qualified Person under NI 43-101.

About Golden Share

Golden Share Mining Corporation is a Canadian junior mining company focusing on exploration in Ontario, the politically stable jurisdiction with a history of rich mineral endowment.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

FOR MORE INFORMATION, CONSULT www.goldenshare.ca OR CONTACT:

Golden Share Mining Corporation

Nick Zeng, President & CEO
Tel: (905) 968-1199
E-mail: info@goldenshare.ca

SOURCE: Golden Share Mining Corporation

ReleaseID: 453948

NEW YORK, NY / ACCESSWIRE / January 31, 2017 / Biotech acquisitions deals are expected to see a substantial jump in 2017 as large pharmaceutical companies look to boost slowing revenues. Already in January we have seen a number of deals announced: Takeda Pharmaceutical’s acquisition of Ariad Pharmaceuticals, Eli Lilly’s acquisition of CoLucid Pharmaceuticals, Inc. and Valeant Pharmaceuticals decision to sell Dendreon Pharmaceuticals. Approximately 43 percent of biopharma executives have said that they had five or more potential deals in progress, which is substantially more than the 6 percent seen last April, according to a poll conducted by Ernst & Young mid-October last year.

“2017 is likely to push biopharma deal making to new heights,” commented Ernst & Young’s Andrew Forman, in a research note titled M&A Outlook and Firepower Report 2017.

Register with us now
for your free membership and gain access to our latest research reports at: RDInvesting.com

“Large drug companies have been making money doing things that are artificial and unsustainable. Like price increases, inversions and financial engineering,” says Brad Loncar, a cancer-company expert at Loncar Investments. “Because those things are coming to an end and the environment for the pharma industry is becoming much more challenging, companies are having a real problem posting revenue growth,” says Loncar. “The only way they can get revenue growth is to buy it.”

Antares Pharma Inc. (NASDAQ: ATRS)

Get Your Up-To-Date Antares Pharma Research
Report Click Here

Antares Pharma’s shares spiked 13.40 percent to close at $2.20 a share Monday. The stock traded between $1.87 and $2.22 on volume of 2.55 million shares traded. Antares Pharma focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. On December 21st, the company announced that it had submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for QuickShot Testosterone (QST).

“The submission of the QST New Drug Application represents yet another significant accomplishment for the Company in 2016. It is the first product designed for subcutaneous delivery of testosterone through a fine gauge needle in patients diagnosed with hypogonadism,” said Robert F. Apple, President and Chief Executive Officer. “We believe QST could be an excellent treatment option for men with hypogonadism.”

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)

Get Your Up-To-Date ACADIA Pharmaceuticals
Research Report Click Here

ACADIA Pharmaceuticals’ shares increased 2.10 percent to close at $32.60 a share Monday. The stock traded between $31.43 and $32.67 on volume of 1.75 million shares traded. ACADIA’s NUPLAZID (pimavanserin) is the first and only medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.

On December 20th, the company reported positive top-line results from its Phase II exploratory study (-019 Study) of pimavanserin in patients with Alzheimer’s disease psychosis (AD Psychosis). In this Phase II exploratory study, pimavanserin met the primary endpoint showing a statistically significant reduction in psychosis versus placebo as measured by the Neuropsychiatric Inventory-Nursing Home (NPI-NH) Psychosis score at week 6 of dosing (p=0.0451).

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 453911

NEW YORK, NY / ACCESSWIRE / January 31,
2017 / Biotech acquisitions deals are expected to see a substantial jump in 2017 as large pharmaceutical companies look to boost slowing revenues. In January we have seen a number of deals announced: Takeda Pharmaceutical’s acquisition of Ariad Pharmaceuticals, Eli Lilly’s acquisition of CoLucid Pharmaceuticals, Inc. and Valeant Pharmaceuticals decision to sell Dendreon Pharmaceuticals. Approximately 43 percent of biopharma executives have said that they had five or more potential deals in progress, which is substantially more than the 6 percent seen last April, according to a poll conducted by Ernst & Young mid-October last year.

“2017 is likely to push biopharma deal making to new heights,” commented Ernst & Young’s Andrew Forman, in a research note titled M&A Outlook and Firepower Report 2017.

Register with us now
for your free membership and gain access to our latest research reports at: RDInvesting.com

“Large drug companies have been making money doing things that are artificial and unsustainable. Like price increases, inversions and financial engineering,” says Brad Loncar, a cancer-company expert at Loncar Investments. “Because those things are coming to an end and the environment for the pharma industry is becoming much more challenging, companies are having a real problem posting revenue growth,” says Loncar. “The only way they can get revenue growth is to buy it.”

Calithera Biosciences Inc. (NASDAQ: CALA)

Get Your Up-To-Date Calithera Biosciences
Research Report Click Here

Calithera Biosciences’ shares soared 46.74 percent to close at $6.75 a share Monday. The stock traded between $5.85 and $7.25 on volume of 10.42 million shares traded. On Monday, January 30th, Incyte Corp. and Calithera Bioscience have announced a global collaboration and license agreement to develop and commercialize CB-1158, a first-in-class, small molecule arginase inhibitor, in hematology and oncology. Under the terms of the agreement Calithera will receive a $45 million up-front payment and an $8 million equity investment from Incyte.

“In this strategic partnership with Incyte, CB-1158 is expected to be evaluated in multiple trials of novel therapeutic combinations, accelerating its development across hematological and oncology indications,” said Susan Molineaux, Ph.D., Calithera’s Chief Executive Officer.

Evoke Pharma Inc. (NASDAQ: EVOK)

Get Your Up-To-Date Evoke Pharma Research
Report Click Here

Evoke Pharma’s shares spiked 14.92 percent to close at $2.85 a share Monday. The stock traded between $2.31 and $2.93 on volume of 1.44 million shares traded. Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. On January 4th, the company announced additional data from the Phase 3 trial of Gimoti.

“As our discussions with the FDA progressed over the past few months, we have continued to analyze data from our Phase 3 trial of Gimoti. These additional analyses have provided us with important insights regarding the efficacy of Gimoti in patients with varying levels of symptom severity, despite not reaching the trial’s primary endpoint,” stated Dave Gonyer, R.Ph., President and CEO.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 453910

TAMPA, FL / ACCESSWIRE / January 31, 2017 / Morphogenesis, Inc., a biotechnology company focused on the development of cell and gene therapies for the treatment of cancer, today announced that the United States Patent and Trademark Office has issued US Patent 9,555,988 covering methods for treating cancer using gene therapy. This proprietary technology is applicable to multiple cancer types and uses a single gene in the form of a small DNA known as a plasmid. Plasmid DNA is considered extremely safe because no live bacteria or viruses are needed for delivery.

The issued patent is an important component of Morphogenesis’ exclusive intellectual property portfolio that includes more than 25 issued patents and patent applications. The DNA patent was awarded under the Cancer Immunotherapy Pilot program, also known as Patents 4 Patients. This program supports the National Cancer Moonshot initiative brought to the forefront by former Vice President Biden and includes fast-track review for cancer immunotherapy-related patent applications without the extra petition fees. From filing to issuance, the patent process took months instead of years.

Morphogenesis’ DNA vaccine has a unique mode of action and is being developed as a direct intratumoral injection. Direct injection is convenient, pain-free, and well-suited for accessible tumors like melanoma. Moreover, the DNA vaccine is relatively inexpensive to manufacture, has a long shelf-life and can be used to treat many different types of cancer.

“This patent is an important component of Morphogenesis’ formidable intellectual property portfolio covering its cancer vaccine technology and provides the Company with 18 year’s protection as it goes into human clinical trials,” said Patricia Lawman, PhD, CEO of Morphogenesis. “The current trend in expedited patent and regulatory review will be extremely beneficial for terminally ill cancer patients and will allow companies to produce products with long-term market exclusivity.”

About Morphogenesis

Morphogenesis, located in Tampa, FL, is developing targeted immunotherapies for the treatment of cancer. The Company’s immunotherapy is based on a single bacterial gene that when expressed in a patient’s tumor cells, educates the immune system to target the patient’s unique set of tumor antigens (neoantigens) without toxic-effects. Morphogenesis has filed an Investigational New Drug (IND) application to test its vaccine in patients with previously-untreated, asymptomatic indolent Non-Hodgkin lymphoma and is filing an IND for intratumoral injection of melanoma at Moffitt Cancer Center.

Contact

Patricia Lawman, PhD, CEO, 813-875-6600
plawman@morphogenesis-inc.com

SOURCE: Morphogenesis

ReleaseID: 453947

VANCOUVER, BC / ACCESSWIRE / January 31, 2017 / Goldsource Mines Inc. (OTC PINK: GXSFF) (TSX-V: GXS) (FRANKFURT: G5M) (the “Company”) is pleased to announce that, due to demand from potential investors, its non-brokered private placement announced on January 16, 2017 has been increased by $1.91 million (or 11,233,450 Units) to up to 26,233,450 Units at a price of $0.17 per Unit for gross proceeds of up to $4,459,686 (the “Offering”). The Company may pay a 6% finders’ fee on part of the Offering. The terms of the Offering and the Units and the proposed use of proceeds are otherwise as previously disclosed.

The Offering is subject to regulatory approval.

NO U.S. REGISTRATION

The securities referred to in this news release have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any applicable securities laws of any state of the United States, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons (as such term is defined in Regulation S under the U.S. Securities Act) or persons in the United States unless registered under the U.S. Securities Act and any other applicable securities laws of the United States or an exemption from such registration requirements is available. This press release does not constitute an offer to sell or a solicitation of an offer to buy any of these securities within any jurisdiction, including the United States.

Ioannis (Yannis) Tsitos
President & Director
Goldsource Mines Inc.

For Further Information:

Goldsource Mines Inc.
Contact: Ioannis (Yannis) Tsitos, President
Fred Cooper, Investor Relations
Telephone: +1 (604) 694-1760
Fax: +1 (604) 694-1761
Toll Free: 1-866-691-1760 (Canada & USA)
Email: info@goldsourcemines.com
Website: www.goldsourcemines.com
570 Granville Street, Suite 501
Vancouver, British Columbia V6C 3P1

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

FORWARD-LOOKING STATEMENTS

This news release contains “forward-looking statements” within the meaning of Canadian securities legislation. Such forward‑looking statements concern the net proceeds from the Offering and the intended use of proceeds. Such forward‑looking statements or information are based on a number of assumptions which may prove to be incorrect. Assumptions have been made regarding, among other things: conditions in general economic and financial markets; timing and amount of capital expenditures; and effects of regulation by governmental agencies. The actual results could differ materially from those anticipated in these forward‑looking statements as a result of risk factors including: the availability of funds; the timing and content of work programs; results of exploration activities of mineral properties; the interpretation of drilling results and other geological data; and general market and industry conditions. Forward‑looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statements were made. The Company undertakes no obligation to update or revise any forward-looking statements included in this news release if these beliefs, estimates and opinions or other circumstances should change, except as otherwise required by applicable law.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

SOURCE: Goldsource Mines Inc.

ReleaseID: 453946

CRYSTAL RIVER, FL / ACCESSWIRE / January 31, 2017 / B-Scada, Inc. (OTCQB: SCDA), a global leader in data acquisition and visualization technology, has been recognized as one of the top 20 IoT Solution Providers of 2017 by CIOReview Magazine.

“It’s a great honor to select B-Scada as one among the 20 Most Promising IoT Solution Providers of 2017,” said Jeevan George, Managing Editor of CIOReview. “B-Scada’s Status Device Cloud is a customizable IoT platform that uses OPC UA information modeling to allow users to connect data from hundreds of different types of hardware for real-time visualization, reporting, archiving, workflow, and other higher level functions.”

B-Scada’s Status Device Cloud is a new IoT PaaS (Platform-as-a-Service) that allows users of any skill level to develop sophisticated IoT solutions using a simple point-and-click interface without any programming.

“Dozens of companies have jumped on the IoT bandwagon to provide IoT solutions,” explains B-Scada CEO, Ron DeSerranno. “However, most of these vendors are only providing API’s and web services which require a great deal of custom programming and development to build a solution. This is time consuming, expensive and risky; with Status Device Cloud solutions can be developed in a few days with far greater functionality, at a fraction of the cost and with no programming.”

Status Device Cloud eliminates many of the barriers to entry into the IoT for many budget-conscious consumers, providing a platform for powerful, far-reaching solutions without the need for a large upfront investment. Learn more at http://scada.com/Software/device-cloud-iot.

Read the full CIO Review article here: http://internet-of-things.cioreview.com/vendor/2017/b-scada

About CIOReview

Published from Fremont, California, CIOReview is a print magazine that explores and understands the plethora of ways adopted by firms to execute the smooth functioning of their businesses. A distinguished panel comprising of CEOs, CIOs, IT VPs including CIOReview editorial board finalized the “20 Most Promising IoT Solution Providers 2017” and shortlisted the best vendors and consultants. For more info, visit: www.cioreview.com.

About B-Scada

B-Scada provides software and hardware solutions for the monitoring and analysis of real time data in the SCADA (Supervisory Control and Data Acquisition), IoT (Internet of Things) and Smart City domains. B-Scada systems are sold worldwide in various verticals including building automation, transportation, smart grid, manufacturing, agriculture and commerce. B-Scada’s IoT and SCADA software platforms are deployed worldwide in a wide range of industries. For more info, visit: www.scada.com.

SOURCE: B-Scada

ReleaseID: 453944

VANCOUVER, BC / ACCESSWIRE / January 31, 2017 / Arizona Silver Exploration Inc. (TSX-V: AZS) (the “Company”) is pleased to announce initial drill results from the first phase of drilling on the Ramsey Mine silver project located in La Paz County, Arizona.

Initial Drill Results

Drill hole R1602-C intersected 50 feet (15.3 metres approximate true width) containing 102 gpt Ag, 0.12% Pb and 0.35% Zn. Within this zone is a higher grade banded amethystine quartz vein 5 feet wide (1.5 metres) of 276 g/tonne (gpt) Ag and 0.5 gpt Au that appears to be the southern extension of the Ramsey vein that was mined historically. The gold content is noteworthy and much to our surprise, in that gold was not previously reported from mine shipments or rock samples from the Ramsey vein. The vein occurs within and near the top of the more extensive lower grade silver zone beneath it. The silver zone is contained within a much thicker section of low grade mineralization that is 91 feet (27.7 metres approximate true width) and grades 63 gpt Ag, 0.09% Pb, and 0.25% Zn. These results confirm the presence of a thick interval of silver, lead, and zinc, as identified by historic long hole drill holes, with newly identified locally elevated gold. This mineral system appears to be large and wide-open to the south of hole R1602-C, where no previous drilling or mine development has occurred.

Drill hole R1603-C was drilled beyond the northern extent of the old underground workings where it was unclear why historic mining was discontinued. R1603-C interested footwall mineralization only, grading 31.3 gpt Ag, 0.08% Pb, and 0.32% Zn with intervals of 0.1-0.2 gpt Au, across 47 feet (14.3 metres approximate true width) after drilling through extremely faulted ground in the region where the high-grade vein projected. We believe the high-grade vein is faulted out, which explains why mining was discontinued historically, along with about 50 feet (15.3 metres) of mineralized section. We interpret the large magnetic anomaly located north of this drill site to represent the faulted extension (see discussion on hydrothermal magnetite below).

Drill hole R1601-C was drilled from the same site at R1602-C, but at a steeper inclination and intersected a mine working where we projected the high-grade vein. This mine working was not on the historical stope maps that predate the MM Sundt Company’s underground activity at the Ramsey Mine in the late 1960s, and probably represents a portion of the high-grade vein that they mined during their tenure on the property. The core drillers were unable to drill past this 7-ft wide mine working, and the hole was abandoned.

Drill holes R1604-C and R1605-C were drilled from the same site as R1603-C, and are currently in the laboratory for sample preparation and analyses, and the results will be reported after they have been received and reviewed.

Magnetic Anomaly

Drilling simultaneously tested the ground magnetic anomaly that is coincident with the old Ramsey Mine workings, in order to understand the source of the magnetic anomaly and to be able to better interpret the much larger (500-meter diameter) ground magnetic anomaly to the north. There is a distinct hydrothermal magnetite zone in the volcanic rocks above the silver target zone in all five holes, explaining the source of the magnetic anomaly and reinforcing the significance of the larger magnetic anomaly to the north. Lab physical property tests also show this rock type is very resistive, probably due to silicification. Magnetic pyrrhotite is also present in the volcanic rocks above and in the silver target zone. Rock physical property tests were performed on representative samples from this magnetite-pyrrhotite zone and confirm a magnetic susceptibility 20-100 times that of the mineralized rocks below the high-grade vein, which explains the ground magnetic anomaly.

The magnetic anomaly to the north of the Ramsey Mine area is significantly stronger and larger than that at the Ramsey Mine. It is located across an inferred fault intersected in drill hole R1603-C and is believed to lie beneath an estimated 30-60 meters of alluvial cover. Silver-mineralized footwall rocks have a higher conductivity and polarization effect than the hanging wall rocks. The lab physical property tests suggest an electrical survey over the large untested magnetite anomaly should help define the geometry of the mineral system in the sub-surface and the locus of any disseminated sulphide minerals. An IP (induced polarization) geophysical survey is being planned to measure the electrical properties of the Ramsey mine are and the larger northern magnetic anomaly. We are encouraged with the results of the programme and have gained further knowledge of the system. Please take a moment to view our web site with images of the core at www.arizonasilverexploration.com.

QA/QC and Analytical Procedures

All drill core is stored in a locked facility in Quartzsite, Arizona prior to transport under strict chain of custody by ALS Minerals personnel to the ALS Minerals laboratory in Tucson Arizona. Core is photographed, sawed, and sampled by ALS Minerals personnel in accordance with sample intervals provided by Arizona Silver, then each interval is crushed to 70% passing 2 mm, a 250 gram split is taken and pulverized to 85% passing 75 microns, subject to a four-acid digestion, and then analyzed by ICP/MS for a 48-element package including silver, lead, and zinc. Samples over 100 ppm silver and over 10,000 ppm lead or zinc are re-analyzed using ICP for higher concentration levels. Selected intervals with high silver values are re-submitted for 1-assay ton fire assays for gold.

Greg Hahn, President and COO and a Certified Professional Geologist (#7122) is the Qualified Person under NI43-101 responsible for preparing and reviewing the data contained in this press release.

ON BEHALF OF THE BOARD

ARIZONA SILVER EXPLORATION INC.

SIGNED: “Greg Hahn”

Greg Hahn, President and Chief Executive Officer
Contact: Greg Hahn (720) 244-2022

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release, and the TSX Venture Exchange has in no way passed upon the merits of the transactions herein.

CAUTION CONCERNING FORWARD-LOOKING STATEMENTS

This news release includes certain forward-looking statements or information. All statements other than statements of historical fact included in this release are forward-looking statements that involve various risks and uncertainties. Forward-looking statements in this news release include statements in relation to the timing, cost and other aspects of the 2016 program on the Ramsey property; the potential for development of the mineral resources; the potential mineralization and geological merits of the Ramsey property; and other future plans, objectives or expectations of the Company. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s plans or expectations include the risk that actual results of current and planned exploration activities, including the results of the Company’s 2016 drilling program(s) on the Ramsey property, will not be consistent with the Company’s expectations; the geology, grade and continuity of any mineral deposits and the risk of unexpected variations in mineral resources, grade and/or recovery rates; fluctuating metals prices; possibility of accidents, equipment breakdowns and delays during exploration; exploration cost overruns or unanticipated costs and expenses; uncertainties involved in the interpretation of drilling results and geological tests; availability of capital and financing required to continue the Company’s future exploration programs and preparation of geological reports and studies; delays in the preparation of geological reports and studies; the metallurgical characteristics of mineralization contained within the Ramsey property are yet to be fully determined; general economic, market or business conditions; competition and loss of key employees; regulatory changes and restrictions including in relation to required permits for exploration activities (including drilling permits) and environmental liability; timeliness of government or regulatory approvals; and other risks detailed herein and from time to time in the filings made by the Company with securities regulators. In connection with the forward-looking information contained in this news release, the Company has made numerous assumptions, including that the Company’s 2016 programs would proceed as planned and within budget. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as otherwise required by applicable securities legislation.

SOURCE: Arizona Silver Exploration Inc.

ReleaseID: 453945

VANCOUVER, BC / ACCESSWIRE / January 31, 2017 / Eureka Resources Inc. (TSX-V: EUK)(OTC PINK: ERKAF)(FRANKFURT: EUS) (“Eureka” or the “Company”) has been informed by Canarc of their exploration plans for the FG Project for 2017. “We are excited about their plans to advance the project,” stated Michael Sweatman Eureka’s CEO.

The FG Gold Project is located in the Cariboo Gold Camp, situated in the historic Quesnel Trough area of central British Columbia and has a long history of continued exploration since the 1970s. A combination of quartz veins and knotted phyllites host gold mineralization containing coarse free gold and finer grained sulphide bearing gold.

The property consists of 33 mineral contiguous mineral claims totaling 10,401 hectares.

Historical exploration has established a Measured and Indicated (376,000 ounces) gold resource at an average grade of 0.776 g/t gold, using a cut-off grade of 0.5 g/t, and an Inferred gold resource (634,900 ounces) at an average grade of 0.718 g/t gold, using a cut-off grade of 0.5 g/t.1

Through drilling, soil sampling, induced polarization (“IP”) geophysical surveys and surface exploration mineralization has been defined over a strike length of 3 kilometres, and has indicated potential for additional mineralization that could extend along an interpreted strike length of over 10 kilometers.

The 2017 exploration program will consist of diamond drilling on the most advanced prospective targets along the northwest extension of the Main Zone that have been identified and conducting soil sampling, prospecting and mapping to follow up on other highly prospective areas of the property that have been identified by geophysics work done on the property.

The 2017 program will focus on the following target areas as shown on Map #1.

__________________
1 The resource is calculated using a cut-off grade of 0.5 g/t. Details of the gold resource can be found in “NI 43-101 Technical Report, Frasergold Exploration Project, Cariboo Mining Division, dated July 27, 2015” available on SEDAR or at the Eureka’s website.

Target #1: Diamond drilling on the projected northwest extension of the Main Zone.

Six to eight diamond drill holes measuring 200 to 300 meters each, totaling approximately 2000 meters, will be drilled into the northwest extension zone and the northwest offset zone.

The drill targets along this northwest projection of the Main Zone have been delineated by coincidental soil and electromagnetic anomalies completed in prior exploration programs. Mapping in this area has also identified lithologies that are similar to the main zone which contains the current historic resources.

Exploration success in this area offers the potential to significantly increase gold resource ounces on the property.

Target #2: Soil sampling in the vicinity of the northwest extension zone

Soil sampling will be completed to fill in areas in the vicinity of the northwest extension to cover a data gap in this area. An area measuring approximately 1,500 by 1,000 meters will be sampled on a 50m X 100 m grid generating approximately 250 to 300 soil samples.

The purpose of this sampling program is to check for mineralization in the soils to identify the presence of other mineralized structures in this area.

Positive results would identify targets for follow up drilling in future exploration programs.

Target #3: Stream sediment, soil sampling, prospecting and mapping along the southern limb of the Eureka syncline.

A 2016 interpretation study of a 2007 geophysical survey interpreted the presence of conductive EM responses to be that of a sedimentary rock package on the south east limb of the Eureka syncline similar to that which hosts gold mineralization within the main zone.

The intent of this program would be to identify and develop targets for future follow up drilling in this new area of the property that offers the potential to significantly increase gold resource ounces on the property.

Prospecting and mapping will also be conducted in the area of the southeast projection of the Main Zone and in the Eureka bowl area.

The exploration program will be conducted during the summer of 2017 with a budget of $500,000.

Map #1: 2017 Exploration Targets

To view an enhanced version of Map #1, please visit:
https://www.accesswire.com/uploads/2017_Exploration_Targets.jpg

Kristian Whitehead P.Geo. is the Company’s designated Qualified Persons for this news release within the meaning of NI 43-101 and has reviewed and approved the technical information described in this news release.

Further information on Eureka can be found on the Company’s website at www.eurekaresourcesinc.com and at www.sedar.com, or by contacting Michael Sweatman, President and CEO, or Bob Ferguson by email info@eurekaresourcesinc.com or by telephone at (604) 449-2273.

Cautionary Statement Regarding Forward-Looking Information

This news release includes certain “forward-looking statements” under applicable Canadian securities legislation that are not historical facts. Forward-looking statements involve risks, uncertainties, and other factors that could cause actual results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements in this news release include, but are not limited to, statements with respect to the Company’s proposed financings, objectives, goals and future exploration plans at the Gemini Project and the FG Project, the costs related to the Company’s proposed exploration programs, and the business and operations of the Company. Forward-looking statements are necessarily based on a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic and social uncertainties; litigation, legislative, environmental and other judicial, regulatory, political and competitive developments; delay or failure to receive board or regulatory approvals; those additional risks set out in the Company’s public documents filed on SEDAR at www.sedar.com; and other matters discussed in this news release. Although the Company believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

SOURCE: Eureka Resources Inc.

ReleaseID: 453942

AUSTIN, TX / ACCESSWIRE / January 31, 2017 / Xplore Technologies Corp. (NASDAQ: XPLR), a global leader in rugged computing announced today that Philip Sassower, Chairman and CEO, and Tom Wilkinson, CFO, will present at the 2017 Disruptive Growth Conference on Thursday, February 16, 2017, at 10:00 am Eastern Time. The event will be held at Convene in New York, NY.

Management will be available to meet with investors February 15 and 16. Investors wishing to schedule a meeting should contact Source Capital or Xplore Investor Relations at xplr@darrowir.com.

A live and archived webcast of the event will be available online through Xplore’s investor relations site at http://www.xploretech.com.

About Xplore Technologies

Xplore is The Rugged Tablet Authority™, exclusively manufacturing powerful, long-lasting, and customer-defined rugged tablet PCs since 1996. Today, Xplore offers the broadest portfolio of genuinely rugged tablets – and the most complete lineup of rugged tablet accessories – on Earth. Its mobility solutions are purpose-built for the energy, utilities, telecommunications, military and defense, manufacturing, distribution, public safety, healthcare, government, and field service sectors. The company’s award-winning military-grade computers are also among the most powerful and longest lasting in their class, built to withstand nearly any hazardous condition or environmental extreme for years without fail. Visit www.xploretech.com for more information on how Xplore and its global channel partners engineer complete mobility solutions to meet specialized workflow demands. Follow us on Twitter, Facebook, LinkedIn, and YouTube.

About Source Capital Group, Inc.

The Investment Banking Group at Source Capital offers a wealth of Wall Street experience to the underserved small cap company sector through its seasoned professionals. They have successfully funded both public and private companies with an emphasis on Structured Credit and unique equity capital markets transactions, creating tailor-made solutions to enhance their clients’ balance sheets. Source Capital Group began as an independent firm specializing in small to medium-sized investment banking transactions. Since 1992, it has grown into a full-service financial institution, while adhering to the highest standards of quality and integrity.

For those interested in attending, please contact Richard Kreger at rkreger@sourcegrp.com or visit www.DisruptNYC.com for more information.

Contact Information:

Tom Wilkinson, Chief Financial Officer
Phone: (512) 637-1162
Email: twilkinson@xploretech.com

Matt Kreps, Darrow Associates Investor Relations
Phone: (512) 696-6401
Email: xplr@darrowir.com

SOURCE: Xplore Technologies Corp.

ReleaseID: 453881